TY  - JOUR

T1  - Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

JO  - The Lancet

UR  - https://eprints.whiterose.ac.uk/id/eprint/181646

PY  - 2022/01/01

AU  - Stuart ASV

AU  - Shaw RH

AU  - Liu X

AU  - Greenland M

AU  - Aley PK

AU  - Andrews NJ

AU  - Cameron JC

AU  - Charlton S

AU  - Clutterbuck EA

AU  - Collins AM

AU  - Darton T et al

ED  - 

DO  - DOI: 10.1016/s0140-6736(21)02718-5

PB  - Elsevier BV

VL  - 399

IS  - 10319

SP  - 36

EP  - 49

Y2  - 2025/11/05

ER  -